Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
In Vivo. 2007 May-Jun;21(3):445-51.

Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones.

Author information

  • 1Department of Internal Medicine, University of South Florida Cardiac Hormone Center, and James A. Haley Veterans Medical Center, Tampa, FL, USA. david.vesely@med.va.gov

Abstract

BACKGROUND:

Four cardiac hormones have anticancer effects in vitro: i) atrial natriuretic peptide (ANP), ii) vessel dilator, iii) long acting natriuretic peptide (LANP), and iv) kaliuretic peptide.

MATERIALS AND METHODS:

These cardiac hormones were infused subcutaneously for 28 days with weekly fresh hormones at 3 nM min(-1) kg(-1) body weight in athymic mice bearing human pancreatic adenocarcinomas.

RESULTS:

ANP, vessel dilator, LANP and kaliuretic peptide eliminated 80%, 33%, 20% and 14% of the pancreatic adenocarcinomas. Even in the treated animals which did not have a total cure, their tumor volume decreased to less than 10% (and with vessel dilator to 2%) of that of the untreated animals. The natriuretic peptide receptor (NPR)-A receptor was decreased 33% to 55% in the metastatic lesions compared to the primary pancreatic adenocarcinoma.

CONCLUSION:

Four cardiac hormones eliminated up to 80% of human pancreatic adenocarcinomas in athymic mice.

PMID:
17591353
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk